Journal
STEM CELLS
Volume 31, Issue 8, Pages 1523-1534Publisher
WILEY
DOI: 10.1002/stem.1397
Keywords
Globoid cell leukodystrophy; Mesenchymal stem cells; multipotent stromal cells; Twitcher mouse; Bone marrow-derived stem cells; Stem cell transplantation
Categories
Funding
- Pathogen Detection and Quantification Core (PDQC) at the TNPRC [RR00164]
- National Institutes of Neurological Disorders and Stroke (NIH) [R21-NS059665]
- Tulane University
Ask authors/readers for more resources
Globoid cell leukodystrophy (GLD) is a common neurodegenerative lysosomal storage disorder caused by a deficiency in galactocerebrosidase (GALC), an enzyme that cleaves galactocerebroside during myelination. Bone marrow transplantation has shown promise when administered to late-onset GLD patients. However, the side effects (e.g., graft vs. host disease), harsh conditioning regimens (e.g., myelosuppression), and variable therapeutic effects make this an unsuitable option for infantile GLD patients. We previously reported modest improvements in the twitcher mouse model of GLD after intracerebroventricular (ICV) injections of a low-dose of multipotent stromal cells (MSCs). Goals of this study were to improve bone marrow-derived MSC (BMSC) therapy for GLD by increasing the cell dosage and comparing cell type (e.g., transduced vs. native), treatment timing (e.g., single vs. weekly), and administration route (e.g., ICV vs. intraperitoneal [IP]). Neonatal twitcher mice received (a) 2 x 10(5) BMSCs by ICV injection, (b) 1 x 10(6) BMSCs by IP injection, (c) weekly IP injections of 1 x 10(6) BMSCs, or (d) 1 x 10(6) lentiviral-transduced BMSCs overexpressing GALC (GALC-BMSC) by IP injection. All treated mice lived longer than untreated mice. However, the mice receiving peripheral MSC therapy had improved motor function (e.g., hind limb strength and rearing ability), twitching symptoms, and weight compared to both the untreated and ICV-treated mice. Inflammatory cell, globoid cell, and apoptotic cell levels in the sciatic nerves were significantly decreased as a result of the GALC-BMSC or weekly IP injections. The results of this study indicate a promising future for peripheral MSC therapy as a noninvasive, adjunct therapy for patients affected with GLD. STEM Cells2013;31:1523-1534
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available